{"id":22596,"date":"2025-09-24T12:35:52","date_gmt":"2025-09-24T16:35:52","guid":{"rendered":"https:\/\/www.arsacs.com\/?p=22596"},"modified":"2026-03-16T18:18:11","modified_gmt":"2026-03-16T22:18:11","slug":"therapeutic-approaches-for-arsacs-drs-benoit-gentil-and-heather-durham-4","status":"publish","type":"post","link":"https:\/\/2026.arsacs.com\/fr\/therapeutic-approaches-for-arsacs-drs-benoit-gentil-and-heather-durham-4\/","title":{"rendered":"&#8220;Therapeutic Approaches for ARSACS&#8221;- Dr. Benoit Gentil and Dr. Heather Durham"},"content":{"rendered":"<p>This research focuses on developing a potential gene therapy for ARSACS, a rare inherited neurological disease. Scientists created a smaller version of the faulty protein (called\u00a0<i>minisacsin<\/i>) that can fit into a viral vector for delivery to nerve cells. In mouse models, early treatment with this therapy delayed or reduced disease symptoms, including movement problems and retinal changes. The team is now testing whether the therapy can also help after symptoms begin.\u00a0 Our results so far provide a better understanding of the ARSACS pathogenesis would complete preclinical studies aiming at developing \u00a0a gene therapy for ARSACS.<\/p>\n<p>Grant: $100,000<\/p>\n<p>Duration: one year<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft  wp-image-3643\" src=\"https:\/\/2026.arsacs.com\/wp-content\/uploads\/2021\/02\/Durham_Benoit_Nov_2017-150x150-2.jpg\" alt=\"\" width=\"199\" height=\"199\" \/><\/p>\n<p>Dr. Benoit Gentil\u00a0 &amp; Dr. Heather Durham<\/p>\n<p><span style=\"font-size: revert;\">Department of Kinesiology and Physical Education, McGill University\u00a0<\/span><\/p>\n<p>475 Pine Avenue West,\u00a0 \u00a0room 210<\/p>\n<p>Montreal (Qu\u00e9bec)\u00a0 H2W 1S4<\/p>\n<p>Contacts: <a href=\"mailto:heather.durham@mcgill.ca\">heather.durham@mcgill.ca<\/a> ; \u00a0\u00a0<a href=\"mailto:benoit.gentil@mcgill.ca\">benoit.gentil@mcgill.ca<\/a><\/p>\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>This research focuses on developing a potential gene therapy for ARSACS, a rare inherited neurological disease. Scientists created a smaller version of the faulty protein (called\u00a0minisacsin) that can fit into a viral vector for delivery to nerve cells. In mouse models, early treatment with this therapy delayed or reduced disease symptoms, including movement problems and [&#8230;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-22596","post","type-post","status-publish","format-standard","hentry","category-current"],"_links":{"self":[{"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/22596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/comments?post=22596"}],"version-history":[{"count":6,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/22596\/revisions"}],"predecessor-version":[{"id":25126,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/22596\/revisions\/25126"}],"wp:attachment":[{"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/media?parent=22596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/categories?post=22596"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/tags?post=22596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}